- 期刊
Antibody against Distinct Cytoplasmic Antigens in Patients Receiving Anti-Hepatitis C Therapy with Interferon and Ribavirin in Taiwan
並列摘要
The aim of the present study was to examine the presence of autoantibodies in patients with hepatitis C virus (HCV) infection receiving combination pegylated interferon (Peg-IFN) and ribavirin therapy. Sera were obtained from 46 patients with HCV infection receiving combination Peg-IFN and ribavirin (Peg-IFN/ribavirin) treatment and 152 patients with HCV infection receiving Peg-IFN therapy only at Chung Shan Medical University Hospital, Taiwan. The serum samples were evaluated for the presence of anticytoplasmic antibody by indirect immunofluorescence assay (IIF) of HEp-2 cells. HEp-2 cells were also cultured with Peg-IFN (100 U/ml), ribavirin (100 μg/ml) and Peg-IFN/ribavirin. Anti-histone antibody (AHA) was determined by ELISA. The rod and ring index (RRI) was calculated by counting the numbers of rods and rings in 100 cells. Patients with HCV infection treated with Peg-IFN/ribavirin had a higher prevalence of anti-cytoplasmic rod and ring (anti-RR) antibodies than those not treated with Peg-IFN/ribavirin. RRI increased with duration of therapy and decreased after discontinuing therapy. When HEp-2 cells were cultured with Peg-IFN/ribavirin or ribavirin, RRI increased with culture time. Further, AHA increased with increasing anti-RR antibody in patients receiving Peg-IFN/ribavirin therapy. In conclusion, anti-RR antibody is found in HCV patients receiving Peg-IFN/ribavirin therapy and the frequency of anti-RR antibody is correlated with therapy time, suggesting that combination Peg- IFN/ribavirin and ribavirin alone play a role in the production of anti-RR antibodies. Anti-RR antibody should be considered a serological marker for patients receiving Peg-IFN/ribavirin therapy.
延伸閱讀
- Hung, Y. H., Yang, C. C., Chen, C. H., Yeh, Y. H., Chen, M. F., & Mo, L. R. (2007). Predictive Factors for Therapeutic Effect of Interferon Alfa-2b and Ribavirin Conbination Therapy on Chronic Hepatitis C: A Retrospective Analysis in a Mid-Taiwan Hospital. 秀傳醫學雜誌, 7(1&2), 15-19. https://www.airitilibrary.com/Article/Detail?DocID=15610497-200704-7-1&2-15-19-a
- Kao, J. H., Lai, M. Y., & Chen, D. S. (2005). Interferon-Based Therapy for the Treatment of Chronic Hepatitis B and C in Taiwan. 臺灣消化醫學雜誌, 22(3), 244-245. https://www.airitilibrary.com/Article/Detail?DocID=10137696-200509-22-3-244-245-a
- Hsiao, C. Y., Chang, C. T., Chen, Y. F., & Yu, K. H. (2021). The Impact of Antiphospholipid Antibody Profile on the Clinical Outcomes Associated with Systemic Lupus Erythematosus in Taiwanese Patients. Formosan Journal of Rheumatology, 35(1), 17-27. https://doi.org/10.6313/FJR.202106_35(1).0003
- 柯維信（2006）。The analysis of hepatitis C treatment with peginterferon alfa 2b and ribavirin in three regional hospitals in Taiwan〔碩士論文，高雄醫學大學〕。華藝線上圖書館。https://www.airitilibrary.com/Article/Detail?DocID=U0011-2306200617455700
- 林雅雲（2006）。Human Leukocyte Antigen Class I and II Alleles in Chronic Hepatitis C Patients: the role in the pathogenesis and response to peginterferon plus ribavirin combination therapy〔碩士論文，高雄醫學大學〕。華藝線上圖書館。https://www.airitilibrary.com/Article/Detail?DocID=U0011-3006200603180800